[Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study].
The expression of Human Epidermal Growth Factor Receptor 2 (HER-2) in tissue and the level of its extracellular domain (ECD/HER-2) in serum have been found to be helpful prognostic factors in many malignancies. THE AIM of this study was to assess the prognostic value of baseline level of ECD/HER-2 in patients with primary osteosarcoma.


METHODS
26 newly-diagnosed osteosarcoma patients aged 6-18 years (median 15 years) were included in the study. Disease localised at presentation (16 patients) and dissemination--stage IV (10 patients).


RESULTS
13-44 months (median 23 months). The serum samples were collected before initial chemotherapy. The serum baseline level of ECD/HER-2 was measured using immunoenzymatic method.


RESULTS
The level of ECD/HER-2 in serum ranged 3.8-14.4 ng/ml; median 5 ng/ml. Disease progression occurred statistically significantly more often in patients with ECD/HER-2 > 5 ng/ml (7/12 patients) than in patients with ECD/HER-2 < or = 5 ng/ml (1/14 patient), P=0.005. High concentration of ECD/HER-2 was also related to decreased overall survival: ECD/HER-2 > 5 ng/ml vs ECD/HER-2 < or = 5 ng/ml: 50% vs 93%; P=0.057.


CONCLUSIONS
The preliminary results from this study indicate that the serum concentration of ECD/HER-2 in patients with osteosarcoma may be a useful marker for predicting course of disease, in particular for detecting early disease progression. However, it is mandatory to make further studies to determine the prognostic role of elevated serum concentrations ECD/HER-2 in osteosarcoma, which also may be a step towards target therapies with monoclonal antibodies against the HER-2 receptor.
Ługowska
Iwona
I
Klinika Chirurgii Onkologicznej Dzieci i Młodziezy IMiD, ul. Kasprzaka 17a, 01-211 Warszawa. kiwonka@wp.pl
Woźniak
Wojciech
W
Ambroszkiewicz
Jadwiga
J
Gajewska
Joanna
J
Szamotulska
Katarzyna
K
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D002648:Child; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000097:blood* / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D010865:Pilot Projects; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human